Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2010

View Archived Issues

Memory Pharmaceuticals claims novel 5-HT6 receptor ligands

Novel MIF inhibitors identified by Yale University scientists for cancer therapy

Phase II data support superiority of OvPlex to CA-125 for diagnosis ovarian cancer

Array BioPharma claims novel Pim kinase inhibitors

GlaxoSmithKline presents new interferon inducers

Schering-Plough and Southern Research Institute claim new antivirals

Sirtris Pharmaceuticals presents novel SIRT modulators

Amgen patents novel Na(V)1.7 sodium channel blockers

Cilostazol may benefit patients with acute ischemic stroke

Array Biopharma presents new D2 receptor antagonists for allergic disease

Paricalcitol improves albuminuria in diabetic nephropathy

Eisai and Johns Hopkins to collaborate on development GCPII inhibitors

Xoma initiates phase II trial of XOMA-052 in type 1 diabetes

FDA grants orphan drug status to BioSante's GVAX pancreatic cancer vaccine

Inspire Pharmaceuticals reports phase II data on Azasite for blepharitis

Savient resubmits Krystexxa BLA for chronic gout to FDA

FDA requests additional information regarding Afrezza NDA for hyperglycemia in diabetes

MicuRx files IND for MRX-I antibiotic in China

UCB presents full-year results 2009

Amylin, Lilly and Alkermes receive FDA's complete response letter on once-weekly exenatide

Bio-Path receives FDA approval for clinical evaluation liposomal Grb-2 in cancer

FDA adds boxed warning to Plavix for reduced effectiveness in poor metabolizers of the drug

Revolade approved in Europe for thrombocytopenia in ITP

Orexigen and Patheon enter into exclusive manufacturing agreement for Contrave

Sigma-Aldrich to sell Pfizer's small-molecule compounds to researchers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...